[{"id":"855e0615-efe8-444c-a20c-79fd80778922","acronym":"","url":"https://clinicaltrials.gov/study/NCT07475923","created_at":"2026-03-28T01:38:45.775Z","updated_at":"2026-03-28T01:38:45.775Z","phase":"","brief_title":"Molecular Surveillance In Early Breast Cancer Using The Tumor-Informed ctDNA Assay Myriad Genetics Precise MRD Test; A Prospective Observational Multicenter Study (The MRD Molecular Surveillance Study)","source_id_and_acronym":"NCT07475923","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • BRCA","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • BRCA mutation • HER-2 negative + HR positive + BRCA mutation","tags":["HER-2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • BRCA mutation • HER-2 negative + HR positive + BRCA mutation"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 08/26/2026","start_date":" 08/26/2026","primary_txt":" Primary completion: 12/31/2031","primary_completion_date":" 12/31/2031","study_txt":" Completion: 12/31/2033","study_completion_date":" 12/31/2033","last_update_posted":"2026-03-17"},{"id":"7b820269-141f-4024-866b-63f1d5de0853","acronym":"S2206","url":"https://clinicaltrials.gov/study/NCT06058377","created_at":"2023-09-28T14:10:22.699Z","updated_at":"2025-02-25T12:29:51.382Z","phase":"Phase 3","brief_title":"Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer","source_id_and_acronym":"NCT06058377 - S2206","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 positive • ER positive • HR positive • HER-2 negative • HR positive + HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER positive • HR positive • HER-2 negative • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • paclitaxel • doxorubicin hydrochloride • cyclophosphamide • daunorubicin"],"overall_status":"Recruiting","enrollment":" Enrollment 3680","initiation":"Initiation: 11/27/2023","start_date":" 11/27/2023","primary_txt":" Primary completion: 05/31/2026","primary_completion_date":" 05/31/2026","study_txt":" Completion: 05/31/2026","study_completion_date":" 05/31/2026","last_update_posted":"2025-02-24"},{"id":"54f667c3-3716-4279-a108-c5768e0f70d9","acronym":"REALNESS","url":"https://clinicaltrials.gov/study/NCT06676436","created_at":"2025-02-25T14:04:59.533Z","updated_at":"2025-02-25T14:04:59.533Z","phase":"","brief_title":"Observational Study on the Treatment of Patients With Metastatic Breast Cancer","source_id_and_acronym":"NCT06676436 - REALNESS","lead_sponsor":"AstraZeneca","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 negative • HR positive + HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative • HR positive + HER-2 negative"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 11/30/2024","start_date":" 11/30/2024","primary_txt":" Primary completion: 11/30/2025","primary_completion_date":" 11/30/2025","study_txt":" Completion: 11/30/2025","study_completion_date":" 11/30/2025","last_update_posted":"2025-02-19"},{"id":"e34a5a55-d8a1-4469-8532-07c6096c4f21","acronym":"KELLY","url":"https://clinicaltrials.gov/study/NCT03222856","created_at":"2021-01-18T15:54:23.632Z","updated_at":"2025-02-25T14:01:19.405Z","phase":"Phase 2","brief_title":"Ph II Study of Pembrolizumab \u0026 Eribulin in Patients With HR+/HER2- MBC Previously Treated With Anthracyclines \u0026 Taxanes","source_id_and_acronym":"NCT03222856 - KELLY","lead_sponsor":"MedSIR","biomarkers":" HER-2 • PD-L1 • ER • PGR • TMB","pipe":" | ","alterations":" PD-L1 expression • HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative","tags":["HER-2 • PD-L1 • ER • PGR • TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Halaven (eribulin mesylate)"],"overall_status":"Completed","enrollment":" Enrollment 44","initiation":"Initiation: 12/14/2017","start_date":" 12/14/2017","primary_txt":" Primary completion: 10/31/2018","primary_completion_date":" 10/31/2018","study_txt":" Completion: 12/23/2020","study_completion_date":" 12/23/2020","last_update_posted":"2025-02-19"},{"id":"d3bd037a-496e-40a7-bdf6-271632f38a73","acronym":"C4391001","url":"https://clinicaltrials.gov/study/NCT04557449","created_at":"2021-01-18T21:47:02.862Z","updated_at":"2025-02-25T16:45:10.545Z","phase":"Phase 1","brief_title":"Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors","source_id_and_acronym":"NCT04557449 - C4391001","lead_sponsor":"Pfizer","biomarkers":" CDKN2A • CCND1 • CD4","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative","tags":["CDKN2A • CCND1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • fulvestrant • letrozole • atirmociclib (PF-07220060) • midazolam hydrochloride"],"overall_status":"Recruiting","enrollment":" Enrollment 337","initiation":"Initiation: 09/23/2020","start_date":" 09/23/2020","primary_txt":" Primary completion: 09/23/2026","primary_completion_date":" 09/23/2026","study_txt":" Completion: 11/23/2027","study_completion_date":" 11/23/2027","last_update_posted":"2025-02-05"},{"id":"ac946163-6425-4f9a-8c1e-f35619d318be","acronym":"ROSE","url":"https://clinicaltrials.gov/study/NCT05377684","created_at":"2022-05-17T11:53:45.438Z","updated_at":"2025-02-25T17:25:34.281Z","phase":"","brief_title":"Study of Quality of Life and Hormone Levels in Premenopausal Participants With Early Breast Cancer Receiving Triptorelin Plus Additional Cancer Treatment","source_id_and_acronym":"NCT05377684 - ROSE","lead_sponsor":"Ipsen","biomarkers":" HER-2 • BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" HR positive • HER-2 negative • HR positive + HER-2 negative • BRCA mutation","tags":["HER-2 • BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • HR positive + HER-2 negative • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e triptorelin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 450","initiation":"Initiation: 06/09/2022","start_date":" 06/09/2022","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2025-01-31"},{"id":"de7c1a81-63eb-4f3b-bbdb-13c3636f54e3","acronym":"","url":"https://clinicaltrials.gov/study/NCT05203445","created_at":"2022-01-24T17:01:46.426Z","updated_at":"2025-02-25T16:17:12.572Z","phase":"Phase 2","brief_title":"A Study of Olaparib and Pembrolizumab in People with Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer","source_id_and_acronym":"NCT05203445","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" HER-2 • PGR • BRCA1 • BRCA2 • RAD51C • RAD51D","pipe":" | ","alterations":" HR positive • HER-2 negative • PALB2 mutation • RAD51C mutation • RAD51D mutation • HR positive + HER-2 negative • HER-2 negative + HR positive + BRCA mutation","tags":["HER-2 • PGR • BRCA1 • BRCA2 • RAD51C • RAD51D"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • PALB2 mutation • RAD51C mutation • RAD51D mutation • HR positive + HER-2 negative • HER-2 negative + HR positive + BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lynparza (olaparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 01/31/2022","start_date":" 01/31/2022","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2025-01-13"},{"id":"fce2d3a2-dfcd-4045-87c5-6fb0389fc58d","acronym":"TBCRC 044","url":"https://clinicaltrials.gov/study/NCT03095352","created_at":"2021-01-18T15:15:08.860Z","updated_at":"2025-02-25T16:05:59.956Z","phase":"Phase 2","brief_title":"Pembrolizumab with Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients with Chest Wall Disease","source_id_and_acronym":"NCT03095352 - TBCRC 044","lead_sponsor":"Hope Rugo, MD","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Herceptin (trastuzumab) • carboplatin"],"overall_status":"Completed","enrollment":" Enrollment 70","initiation":"Initiation: 09/02/2017","start_date":" 09/02/2017","primary_txt":" Primary completion: 11/30/2024","primary_completion_date":" 11/30/2024","study_txt":" Completion: 11/30/2024","study_completion_date":" 11/30/2024","last_update_posted":"2025-01-06"},{"id":"f17e9f3e-aca2-40fd-9842-6769913d6623","acronym":"","url":"https://clinicaltrials.gov/study/NCT02520063","created_at":"2021-01-18T12:10:45.080Z","updated_at":"2025-02-25T15:42:33.018Z","phase":"Phase 1/2","brief_title":"Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer","source_id_and_acronym":"NCT02520063","lead_sponsor":"University of Alabama at Birmingham","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative • HR positive + HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • letrozole • carotuximab IV (ENV-105)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 02/23/2019","start_date":" 02/23/2019","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-12-27"},{"id":"487ee4b2-c7db-42c0-bff9-3a4c527f6659","acronym":"FITWISE","url":"https://clinicaltrials.gov/study/NCT06518837","created_at":"2025-02-26T08:20:06.718Z","updated_at":"2025-02-26T08:20:06.718Z","phase":"Phase 2","brief_title":"Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer","source_id_and_acronym":"NCT06518837 - FITWISE","lead_sponsor":"Rutgers, The State University of New Jersey","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative • HR positive + HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • HR positive + HER-2 negative"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 10/30/2024","start_date":" 10/30/2024","primary_txt":" Primary completion: 09/30/2027","primary_completion_date":" 09/30/2027","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2024-12-02"},{"id":"72e92596-829c-4510-aace-4fcdc49a7712","acronym":"YL202-INT-101-01","url":"https://clinicaltrials.gov/study/NCT05653752","created_at":"2022-12-16T14:58:14.992Z","updated_at":"2025-02-25T12:38:28.921Z","phase":"Phase 1","brief_title":"A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer","source_id_and_acronym":"NCT05653752 - YL202-INT-101-01","lead_sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","biomarkers":" EGFR • HER-2","pipe":" | ","alterations":" EGFR mutation • HR positive • HER-2 negative • EGFR L858R • EGFR exon 19 deletion • HR positive + HER-2 negative","tags":["EGFR • HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • HR positive • HER-2 negative • EGFR L858R • EGFR exon 19 deletion • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BNT326"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 12/20/2022","start_date":" 12/20/2022","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-11-15"},{"id":"4ac5d169-3685-4152-89c9-4a9f3005ecae","acronym":"","url":"https://clinicaltrials.gov/study/NCT02999477","created_at":"2021-01-18T14:45:19.842Z","updated_at":"2025-02-25T16:05:35.986Z","phase":"Phase 1","brief_title":"A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer","source_id_and_acronym":"NCT02999477","lead_sponsor":"Adrienne G. Waks","biomarkers":" HER-2 • PD-L1 • PGR","pipe":" | ","alterations":" PD-L1 expression • HR positive • HER-2 negative • HR positive + HER-2 negative","tags":["HER-2 • PD-L1 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HR positive • HER-2 negative • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • albumin-bound paclitaxel"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 02/23/2017","start_date":" 02/23/2017","primary_txt":" Primary completion: 11/20/2022","primary_completion_date":" 11/20/2022","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2024-11-06"},{"id":"278a467f-a574-4f60-bfe8-46b39583941f","acronym":"BTCRC-BRE19-409","url":"https://clinicaltrials.gov/study/NCT04762979","created_at":"2021-02-21T13:52:26.673Z","updated_at":"2025-02-25T15:44:20.914Z","phase":"Phase 2","brief_title":"Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer","source_id_and_acronym":"NCT04762979 - BTCRC-BRE19-409","lead_sponsor":"Marina N Sharifi","biomarkers":" HER-2 • PIK3CA","pipe":" | ","alterations":" HER-2 amplification • HER-2 negative • PIK3CA mutation • HR positive + HER-2 negative","tags":["HER-2 • PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • HER-2 negative • PIK3CA mutation • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Piqray (alpelisib) • fulvestrant"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 02/12/2021","start_date":" 02/12/2021","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2024-10-30"},{"id":"1c9daf03-acbe-412b-99d6-f63aac6d1d20","acronym":"EVER-132-002","url":"https://clinicaltrials.gov/study/NCT04639986","created_at":"2021-01-19T20:38:27.058Z","updated_at":"2024-07-02T16:34:26.121Z","phase":"Phase 3","brief_title":"Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)","source_id_and_acronym":"NCT04639986 - EVER-132-002","lead_sponsor":"Gilead Sciences","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • Trodelvy (sacituzumab govitecan-hziy)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 331","initiation":"Initiation: 11/23/2020","start_date":" 11/23/2020","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-06-14"},{"id":"cb5da6dd-a9b6-436a-acd6-01685f4f5bc2","acronym":"ETHAN","url":"https://clinicaltrials.gov/study/NCT05501704","created_at":"2022-08-15T12:10:47.553Z","updated_at":"2024-07-02T16:34:37.326Z","phase":"Phase 2","brief_title":"ETHAN - ET for Male BC","source_id_and_acronym":"NCT05501704 - ETHAN","lead_sponsor":"Jose Pablo Leone","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • anastrozole • Firmagon (degarelix) • Soltamox (tamoxifen citrate)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 10/11/2023","start_date":" 10/11/2023","primary_txt":" Primary completion: 04/01/2026","primary_completion_date":" 04/01/2026","study_txt":" Completion: 04/01/2036","study_completion_date":" 04/01/2036","last_update_posted":"2024-06-07"},{"id":"b9f11a37-1639-484b-871b-ebf817da5120","acronym":"","url":"https://clinicaltrials.gov/study/NCT05488145","created_at":"2022-08-04T14:55:33.817Z","updated_at":"2024-07-02T16:34:37.681Z","phase":"","brief_title":"A Feasibility Trial of a Web Based App Intervention in Hormone Positive Breast Cancer Patients to Improve Adherence to Endocrine Therapy","source_id_and_acronym":"NCT05488145","lead_sponsor":"Emory University","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative • HR positive + HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • HR positive + HER-2 negative"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 03/21/2023","start_date":" 03/21/2023","primary_txt":" Primary completion: 10/30/2024","primary_completion_date":" 10/30/2024","study_txt":" Completion: 05/30/2025","study_completion_date":" 05/30/2025","last_update_posted":"2024-06-06"},{"id":"ded04c2b-2ead-4cff-9660-0481bc077bfe","acronym":"MORPHEUS","url":"https://clinicaltrials.gov/study/NCT03280563","created_at":"2021-01-18T16:11:59.285Z","updated_at":"2024-07-02T16:34:37.795Z","phase":"Phase 1/2","brief_title":"A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer","source_id_and_acronym":"NCT03280563 - MORPHEUS","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2 • PD-L1","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive","tags":["HER-2 • PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • tamoxifen • Verzenio (abemaciclib) • fulvestrant • ipatasertib (RG7440) • exemestane • Jingzhuda (entinostat)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 138","initiation":"Initiation: 12/26/2017","start_date":" 12/26/2017","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-06-06"},{"id":"b30a8bca-2be6-49b4-90f3-03ff7a00b1ad","acronym":"","url":"https://clinicaltrials.gov/study/NCT04586270","created_at":"2021-01-18T21:52:48.356Z","updated_at":"2024-07-02T16:34:37.959Z","phase":"Phase 1","brief_title":"A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer","source_id_and_acronym":"NCT04586270","lead_sponsor":"Taiho Oncology, Inc.","biomarkers":" HER-2 • KRAS • PTEN • NF1","pipe":" | ","alterations":" KRAS mutation • HR positive • KRAS G12C • HER-2 negative • KRAS G12D • NF1 mutation • KRAS G12 • HR positive + HER-2 negative","tags":["HER-2 • KRAS • PTEN • NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • HR positive • KRAS G12C • HER-2 negative • KRAS G12D • NF1 mutation • KRAS G12 • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TAS0612"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 10/15/2020","start_date":" 10/15/2020","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2024-06-05"},{"id":"8637b136-3de4-40fa-8293-aa26c472595a","acronym":"SERENA-6","url":"https://clinicaltrials.gov/study/NCT04964934","created_at":"2021-07-16T13:53:17.689Z","updated_at":"2024-07-02T16:34:59.080Z","phase":"Phase 3","brief_title":"Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)","source_id_and_acronym":"NCT04964934 - SERENA-6","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HR positive • HER-2 negative • ER mutation • ESR1 mutation • HR positive + HER-2 negative • PTEN mutation + HR positive","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HR positive • HER-2 negative • ER mutation • ESR1 mutation • HR positive + HER-2 negative • PTEN mutation + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • letrozole • anastrozole • camizestrant (AZD9833)"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 06/30/2021","start_date":" 06/30/2021","primary_txt":" Primary completion: 04/25/2025","primary_completion_date":" 04/25/2025","study_txt":" Completion: 11/26/2027","study_completion_date":" 11/26/2027","last_update_posted":"2024-06-04"},{"id":"36b77ad5-dd89-44e9-832d-efcd80699ed3","acronym":"BRIGHT-2","url":"https://clinicaltrials.gov/study/NCT05077449","created_at":"2021-10-14T19:57:30.329Z","updated_at":"2025-02-25T17:12:02.648Z","phase":"Phase 3","brief_title":"A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer","source_id_and_acronym":"NCT05077449 - BRIGHT-2","lead_sponsor":"Xuanzhu Biopharmaceutical Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative • HR positive + HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • Xuan Yue Ning (bireociclib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 11/16/2021","start_date":" 11/16/2021","primary_txt":" Primary completion: 02/22/2024","primary_completion_date":" 02/22/2024","study_txt":" Completion: 11/01/2029","study_completion_date":" 11/01/2029","last_update_posted":"2024-05-24"},{"id":"c843add6-2e43-4d23-8107-33b91cef77fc","acronym":"","url":"https://clinicaltrials.gov/study/NCT05012813","created_at":"2021-08-19T14:52:52.060Z","updated_at":"2024-07-02T16:35:01.896Z","phase":"","brief_title":"Humidified Forest Oils for Immune System Recovery in Stage I-III Breast or Prostate Cancer","source_id_and_acronym":"NCT05012813","lead_sponsor":"OHSU Knight Cancer Institute","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative • HR positive + HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • HR positive + HER-2 negative"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 30","initiation":"Initiation: 07/19/2022","start_date":" 07/19/2022","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-05-22"},{"id":"41c79a8f-32f5-4120-a3a7-4d561141ced0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04553133","created_at":"2021-01-18T21:46:10.057Z","updated_at":"2024-07-02T16:35:03.345Z","phase":"Phase 1/2","brief_title":"PF-07104091 as a Single Agent and in Combination Therapy","source_id_and_acronym":"NCT04553133","lead_sponsor":"Pfizer","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • fulvestrant • letrozole • tegtociclib (PF-07104091)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 154","initiation":"Initiation: 09/16/2020","start_date":" 09/16/2020","primary_txt":" Primary completion: 03/06/2025","primary_completion_date":" 03/06/2025","study_txt":" Completion: 03/06/2025","study_completion_date":" 03/06/2025","last_update_posted":"2024-05-16"},{"id":"e915b737-ffd0-45cb-831e-4df90b73590c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02206984","created_at":"2021-01-18T10:20:00.102Z","updated_at":"2024-07-02T16:35:03.969Z","phase":"Phase 2","brief_title":"Endocrine Response in Women With Invasive Lobular Breast Cancer","source_id_and_acronym":"NCT02206984","lead_sponsor":"Priscilla McAuliffe","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • fulvestrant • anastrozole"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 201","initiation":"Initiation: 09/30/2015","start_date":" 09/30/2015","primary_txt":" Primary completion: 07/31/2024","primary_completion_date":" 07/31/2024","study_txt":" Completion: 07/31/2024","study_completion_date":" 07/31/2024","last_update_posted":"2024-05-14"},{"id":"ce3343fa-10fb-4d25-ac60-a52a8f5d035a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05374915","created_at":"2022-05-16T12:54:38.932Z","updated_at":"2024-07-02T16:35:04.494Z","phase":"Phase 2","brief_title":"Efficacy and Safety Study of REM-001 Photodynamic Therapy for Treatment of Cutaneous Metastatic Breast Cancer (CMBC)","source_id_and_acronym":"NCT05374915","lead_sponsor":"Kintara Therapeutics, Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e REM-001 therapy"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 02/12/2024","start_date":" 02/12/2024","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-10"}]